Breaking News Instant updates and real-time market news.

AGIO

Agios Pharmaceuticals

$38.88

-0.19 (-0.49%)

, BMY

Bristol-Myers

$57.03

-0.56 (-0.97%)

07:05
12/02/19
12/02
07:05
12/02/19
07:05

Agios Pharmaceuticals appoints Bruce Car as CSO

Agios Pharmaceuticals (AGIO) announced the appointment of Bruce Car, Ph.D., as chief scientific officer effective January 6, 2020. Car will replace Scott Biller, Ph.D., who will retire at the end of 2019 and remain a strategic advisor to Agios through 2020 as previously announced. Car spent 25 years at Bristol-Myers Squibb (BMY) and its legacy companies, working across all therapeutic areas and drug modalities, and serving most recently as the interim head, BMS drug discovery.

AGIO

Agios Pharmaceuticals

$38.88

-0.19 (-0.49%)

BMY

Bristol-Myers

$57.03

-0.56 (-0.97%)

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 13

    Dec

AGIO Agios Pharmaceuticals
$38.88

-0.19 (-0.49%)

10/28/19
PIPR
10/28/19
NO CHANGE
Target $70
PIPR
Overweight
Agios Pharmaceuticals price target lowered to $70 from $80 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target for Agios Pharmaceuticals to $70 from $80 after initial clinical data from AG-270's methylthioadenosine phosphorylase program yielded low monotherapy activity, as expected. The analyst we believes it is prudent to remove AG-270 from his model. However, he keeps an Overweight rating on Agios saying the shares "are at a floor and that significant value can still be created" from mitapivat, DHODH, or eventually methylthioadenosine phosphorylase.
11/05/19
SBSH
11/05/19
NO CHANGE
Target $64
SBSH
Buy
Agios Pharmaceuticals price target lowered to $64 from $80 at Citi
Citi analyst Mohit Bansal lowered his price target for Agios Pharmaceuticals to $64 from $80 saying the company's announcement, based on the FDA feedback, to wait for overall survival data for filing makes him less confident in the cholangio approval. However, the analyst does not think the Street was giving much credit to cholangio. He keeps a Buy rating on Agios.
11/24/19
PIPR
11/24/19
NO CHANGE
PIPR
Overweight
Piper Jaffray reiterates Overweight on Agios after 'encouraging' SNO update
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $70 price target on Agios following the company's "encouraging" IDH/glioma update at the Society for Neuro-Oncology, or SNO. The analyst believes the perioperative results are "promising" given the response and disease control rates observed, and believes the "high DCR suggests that IDH inhibition is proving a meaningful, durable treatment benefit." Van Buren said that this could ultimately become a $500M opportunity that is not currently modeled.
11/26/19
CANT
11/26/19
INITIATION
Target $64
CANT
Overweight
Agios Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young initiated coverage of Agios Pharmaceuticals with an Overweight rating and $64 price target. Although shares were under pressure in 2019, there are catalysts on the horizon and overhangs lifted like financing "that should clear the way for 2020 outperformance," Young tells investors in a research note. She believes Agios has a "robust R&D engine" focused on cellular metabolism and precision medicine for cancer and rare genetic diseases.
BMY Bristol-Myers
$57.03

-0.56 (-0.97%)

11/22/19
MSCO
11/22/19
INITIATION
Target $60
MSCO
Equal Weight
Bristol-Myers resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Risinger resumed coverage of Bristol-Myers with an Equal Weight rating and $60 price target following the closing of the acquisition of Celgene. The deal makes Bristol "a top global cancer company" and he sees solid near-term growth, but he also believes that the combined company faces erosion over the longer-term for key franchises and he prefers to wait for further pipeline developments, Risinger tells investors.
11/25/19
MZHO
11/25/19
INITIATION
Target $3.14
MZHO
Buy
Bristol-Myers Squibb CVR initiated with a Buy at Mizuho
Mizuho analyst Salim Syed initiated coverage of Bristol-Myers Squibb CVR with a Buy rating and $3.14 price target.
11/27/19
GABE
11/27/19
INITIATION
GABE
Buy
Bristol-Myers Squibb CVR initiated with a Buy at Gabelli
Gabelli analyst Kevin Kedra initiated coverage of Bristol-Myers Squibb CVR (BMY-R) with a Buy rating and private market value estimate of $3.50. CVR holders will receive a $9.00 payout if all three of the FDA approval milestones are met, Kedra tells investors in a research note. The analyst sees an 80% probability for the ozanimod milestone, an 86% probability for JCAR017, and 68% probability for bb2121. He recommends the Bristol-Myers CVR as an attractive risk/reward opportunity with multiple near-term catalysts.
11/27/19
11/27/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Vonage (VG) initiated with a Neutral at JPMorgan. 2. Bristol-Myers Squibb CVR (BMY-R, BMY) initiated with a Buy at Gabelli. 3. Novus Therapeutics (NVUS) initiated with a Buy at H.C. Wainwright. 4. KushCo Holdings (KSHB) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AEE

Ameren

$74.58

0.6 (0.81%)

05:01
12/11/19
12/11
05:01
12/11/19
05:01
Initiation
Ameren initiated  »

Ameren initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMK

GenMark

$5.58

-0.04 (-0.71%)

05:00
12/11/19
12/11
05:00
12/11/19
05:00
Downgrade
GenMark rating change  »

GenMark downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$57.40

0.08 (0.14%)

04:59
12/11/19
12/11
04:59
12/11/19
04:59
Downgrade
Dentsply Sirona rating change  »

Dentsply Sirona…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBI

Texas Capital

$61.90

-1.55 (-2.44%)

, IBTX

Independent Bank

$59.90

-1.74 (-2.82%)

04:56
12/11/19
12/11
04:56
12/11/19
04:56
Upgrade
Texas Capital, Independent Bank rating change  »

Texas Capital upgraded to…

TCBI

Texas Capital

$61.90

-1.55 (-2.44%)

IBTX

Independent Bank

$59.90

-1.74 (-2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
William Blair insurance analyst to hold a luncheon meeting »

Insurance Analyst Adam…

QMCO

Quantum

$0.00

(0.00%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Quantum management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TCBK

TriCo Bancshares

$39.02

0.24 (0.62%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
TriCo Bancshares management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

DMTK

DermTech

$12.90

-1.56 (-10.79%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
DermTech management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Oppenheimer healthcare analysts to hold a KOL dinner meeting »

Analysts hold a Cardiac…

MIC

Macquarie Infrastructure

$42.82

-0.02 (-0.05%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Macquarie Infrastructure management to meet with Suntrust »

Group Dinner with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
BTIG oil and tanker analysts to hold a roundtable »

Oil Flow & Tanker…

SPAR

Spartan Motors

$17.68

-0.36 (-2.00%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Spartan Motors management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

04:55
12/11/19
12/11
04:55
12/11/19
04:55
General news
Breaking General news story  »

Week of 12/6 EIA…

LIVN

LivaNova

$79.89

-0.57 (-0.71%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
LivaNova management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

PRFT

Perficient

$42.37

0.03 (0.07%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Perficient management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

VGR

Vector Group

$13.04

0.3 (2.35%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Vector Group management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

LEA

Lear

$125.22

-0.425 (-0.34%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Lear management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CRAI

CRA International

$52.81

0.41 (0.78%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
CRA International management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CONN

Conn's

$13.60

-6.91 (-33.69%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Conn's management to meet with Oppenheimer »

Dinner Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

DSX

Diana Shipping

$3.36

-0.015 (-0.45%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Diana Shipping management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BCOV

Brightcove

$8.93

-0.28 (-3.04%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Brightcove management to meet with Northland »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

04:55
12/11/19
12/11
04:55
12/11/19
04:55
General news
Treasury Budget to be reported at 14:00 »

November Treasury Budget…

ACAD

Acadia

$46.25

-1.7 (-3.55%)

, AXSM

Axsome Therapeutics

$48.70

3.545 (7.85%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call »

Biotech Analyst Duncan,…

ACAD

Acadia

$46.25

-1.7 (-3.55%)

AXSM

Axsome Therapeutics

$48.70

3.545 (7.85%)

BHVN

Biohaven Pharmaceutical

$53.89

0.92 (1.74%)

DNLI

Denali Therapeutics

$18.15

-0.14 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ALNA

Allena Pharmaceuticals

$2.00

0.02 (1.01%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

AZN

AstraZeneca

$47.96

0.2 (0.42%)

, CLPBY

Coloplast

$0.00

(0.00%)

04:55
12/11/19
12/11
04:55
12/11/19
04:55
Conference/Events
Credit Suisse to hold a field trip »

8th Annual European…

AZN

AstraZeneca

$47.96

0.2 (0.42%)

CLPBY

Coloplast

$0.00

(0.00%)

GNNDY

GN Store Nord

$0.00

(0.00%)

GSK

GlaxoSmithKline

$46.13

0.5 (1.10%)

IPSEY

Ipsen

$0.00

(0.00%)

LZAGY

Lonza

$0.00

(0.00%)

NVO

Novo Nordisk

$56.95

0.27 (0.48%)

NVS

Novartis

$92.79

0.24 (0.26%)

RHHBY

Roche

$0.00

(0.00%)

SNN

Smith & Nephew

$44.38

0.285 (0.65%)

SNY

Sanofi

$48.06

2.765 (6.10%)

SONVY

Sonova

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 16

    Dec

  • 17

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.